南威軟件(603636.SH):終止投資北京凱普林光電科技股份有限公司
格隆匯12月18日丨南威軟件(603636.SH)發佈公吿,公司基於自身戰略規劃調整,聚焦主營業務發展,綜合考慮各種相關因素,經審慎研究及各方友好協商,決定終止本次投資事項並擬與凱普林、北京水木韶華科技發展合夥企業(有限合夥)、陳曉華先生及趙鴻飛先生簽署《北京凱普林光電科技股份有限公司增資協議之補充協議(二)》,自協議生效之日起,公司不再履行出資義務,公司自始不享有在凱普林的各項股東權益及原增資協議中的各項權利,協議其他方放棄追究就公司退出該投資事項的任何違約或損失賠償等法律責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.